OMG and neuromyelitis optica: Since first approval in 1995, it is known that MMF is well-tolerated, with few severe complications, and is effective in many autoimmune disorders, including lupus, systemic sclerosis, myasthenia gravis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody disease (15–21).